CN102008480A - Irbesartan-containing composite preparation for treating hypertension - Google Patents
Irbesartan-containing composite preparation for treating hypertension Download PDFInfo
- Publication number
- CN102008480A CN102008480A CN 201010230997 CN201010230997A CN102008480A CN 102008480 A CN102008480 A CN 102008480A CN 201010230997 CN201010230997 CN 201010230997 CN 201010230997 A CN201010230997 A CN 201010230997A CN 102008480 A CN102008480 A CN 102008480A
- Authority
- CN
- China
- Prior art keywords
- irbesartan
- levoamlodipine
- levamlodipine
- blood pressure
- composite preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an irbesartan-containing composite preparation for treating hypertension, which is prepared from the following main components of levoamlodipine or levoamlodipine pharmaceutical salt, hydrochlorothiazide, irbesartan or pharmaceutical salt thereof and an auxiliary component of a pharmaceutical carrier, wherein in per unit of the preparation, the use level of the levoamlodipine or the levoamlodipine pharmaceutical salt is 2.5-10.0mg on the basis of the levoamlodipine. The composite preparation has the advantages of enhancing the curative effect according to the action mechanism that the joint administration fully plays the role of medicament complementation, reaching the standard quickly, ensuring the qualification rate of blood pressure to be 80%, being favorable to the reduction of adverse reaction related to a certain increased dosage, and lasting longer action time. The composite preparation has the characteristics of quick effect, high qualification rate of blood pressure, less side effect and low cost.
Description
Technical field:
The present invention relates to a kind of compound preparation that hypertension contains irbesartan for the treatment of, belong to drug world.
Background technology:
Along with China's rapid growth of economy, the drastic change of people life style, the acceleration of urbanization, aging, the cardiovascular diseases has become first or second cause of the death of rural and urban population.Especially patients with hypertension, its sickness rate accounts for total population about 15%.Morbidity colony is so big, seeks medicine evident in efficacy, that side effect is little and seems more important.
The hypertensive medicine of treatment has multiple at present, such as calcium antagonist (CCBs), converting enzyme inhibitor (ACEI), Angiotensin (ARBs) etc., but single medicine treatment hypertension is difficult up to standard in a short time, and Most patients need be taken two or more antihypertensive drug can reach the blood pressure lowering target.Especially blood pressure exceeds desired value 20/10mmHg, and beginning need be taken two kinds of medicines often.Single medicine is prone to drug resistance, and because the bigger probability that toxicity occurs of dosage is also bigger.Majority is to give two or more drug administration treatments simultaneously.But several drugs is taken simultaneously, and patient's compliance is poor, and the collocation of the dosage of several drugs is not because the problem of formulation dosage and doctor's the degree of awareness often are optimized proportionings.In recent years, though the depressor of much new good effect few side effects is arranged, the controlling blood pressure compliance rate is relatively low.But drug combination can be used two or more depressor, and the dosage of every kind of medicine is little, and the therapeutical effect of medicine should have collaborative or the effect of addition at least, and its ill effect can be cancelled out each other or not overlapping at least or addition.Medicine kind number used during drug combination is too much unsuitable, and crossing to have complicated drug interaction at most.Therefore, select to merge very difficulty of medication amount and kind, need a large amount of development tests.
Therefore, a kind of new treatment pattern is applied to clinical gradually, and the compound hypertension medicine preparation is internationally recognized a kind of orientation treatment.Because the compound antihypertensive drug prescription is followed the principle that different mechanism of action medicines carry out proportioning usually, therefore show as the advantage that increases curative effect or reduce side effect, obtained better controlling of blood pressure effect.
Summary of the invention:
The object of the present invention is to provide a kind of side effect little, taking convenience can effectively be treated the compound preparation of hypertensive three kinds of antihypertensive drugs, and this compound preparation is controlling blood pressure effectively.
Purpose of the present invention is implemented by following technical scheme: a kind ofly treat the compound preparation that hypertension contains irbesartan, include following composition: Levamlodipine (Levamlodipine) or Levamlodipine officinal salt, hydrochlorothiazide (hydrochlorothiazide), irbesartan (irbesartan) or its officinal salt are Main Ingredients and Appearance, being equipped with pharmaceutically suitable carrier forms, in wherein every preparation unit, described Levamlodipine (Levamlodipine) or Levamlodipine officinal salt, count 2.5-10.0mg with Levamlodipine, described irbesartan (irbesartan) or its officinal salt, count 27.5-300.0mg with irbesartan, described hydrochlorothiazide (hydrochlorothiazide) is 6.25-25.0mg.
It is a kind of that to treat the compound preparation that hypertension contains irbesartan be capsule, soft capsule, granule, tablet, powder, controlled release agent or injection dosage form.
Advantage of the present invention: be to give full play to the complementary mechanism of action of medicine according to drug combination to increase curative effect, up to standard fast, make the blood pressure compliance rate reach 80%, reduce with a certain dosage and increase relevant untoward reaction.Compound formulation of the present invention has instant effect, blood pressure compliance rate height, and side effect is little, the characteristics that cost is low.
The specific embodiment:
Further set forth medicine of the present invention by the following examples, these embodiment are only presented for purposes of illustration, do not limit the scope of the invention.
Embodiment 1-4 is listed as follows:
Use the conventional method in the pharmaceuticals industry among the embodiment, the according to the form below formulation becomes tablet, makes the used pharmaceutically suitable carrier of tablet--and adjuvant is the conventional adjuvant of this area.Wherein the proportioning of its Main Ingredients and Appearance is as follows:
| Embodiment | Count (mg/ sheet) with Levamlodipine | Count (mg/ sheet) with irbesartan | Hydrochlorothiazide (mg/ sheet) |
| 1 | Levamlodipine 2.5 | Irbesartan 27.5 | Hydrochlorothiazide 6.25 |
| 2 | Levamlodipine 2.5 | Irbesartan 300.0 | Hydrochlorothiazide 12.5 |
| 3 | Levamlodipine 5.0 | Irbesartan 150.0 | Hydrochlorothiazide 25.0 |
| 4 | Levamlodipine 10.0 | Irbesartan 300.0 | Hydrochlorothiazide 12.5. |
Use the conventional method in the pharmaceuticals industry simultaneously among the embodiment, can also be prepared into capsule, soft capsule, granule, powder, controlled release agent or injection dosage form,, pharmaceutically suitable carrier--used adjuvant is the conventional adjuvant of this area of this dosage form.
Embodiment 5: the present invention treats hypertensive compound preparation clinical trial:
Below will be by human body pharmacodynamic experiment explanation pharmaceutical composition of the present invention to hypertensive therapeutical effect.
1, physical data:
Clinical 400 routine hypertension philtrums, age 40--50 year, 140 examples; Age 51--60 year, 140 examples, age 61--70 year, 120 examples.
2, diagnostic criteria: according to " Chinese hypertension prevention and control guide ", hypertension is defined as: do not obey under the antihypertensive situation systolic pressure 〉=140mmHg and/or diastolic pressure 〉=90mmHg.
3, Therapeutic Method:, adopt randomized to be divided into 4 groups, every group of this compound formulation medicine that adopts embodiment of the invention 1-4 gained respectively with 400 routine hypertensive patients, make tablet, every day is once oral, according to the dose difference of tablet, each a slice or two took 6 days.
4, efficacy assessment standard:
Draft according to " Chinese hypertension prevention and control guide ".The target of antihypertensive therapy is blood pressure to be returned to " normally " or " ideal " level.40-60 year patient be depressurized to ideal or normal arterial pressure (≤130/85mmHg), 60-70 year patient be depressurized at least normal high value (≤140/90mmHg).
5, therapeutic outcome: administration begins to carry out respectively in the 1st day, 2 days, 3 days, 4 days, 5 days, 6 days blood pressure determination.The result shows that medication is after 6 days, 4 groups of the embodiment of the invention are totally 400 routine hypertension philtrums, and it is up to standard to amount to 320 routine patient's blood pressures, promptly returns to " normally " or " ideal " level, mean blood pressure compliance rate 80% illustrates that the present embodiment compound medicine has good curing hypertension effect.
Curative effect sees the following form:
| Case load | Blood pressure case sum up to standard | The below standard case sum of blood pressure | The mean blood pressure compliance rate |
| 400 | 320 | 80 | 80％ |
Discuss
This product is the hypertensive compound formulation of treatment, its blood pressure compliance rate higher 80%.
Claims (2)
1. treat the compound preparation that hypertension contains irbesartan for one kind, it is characterized in that, it includes following composition: Levamlodipine or Levamlodipine officinal salt, hydrochlorothiazide, irbesartan or its officinal salt be Main Ingredients and Appearance, be equipped with pharmaceutically suitable carrier forms, in wherein every preparation unit, described Levamlodipine or Levamlodipine officinal salt, count 2.5-10.0mg with Levamlodipine, described irbesartan or its officinal salt, count 27.5-300.0mg with irbesartan, described hydrochlorothiazide is 6.25-25.0mg.
2. a kind of hypertensive compound preparation that comprises irbesartan for the treatment of according to claim 1 and 2 is characterized in that described compound preparation is capsule, soft capsule, granule, tablet, powder, controlled release agent or injection dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010230997 CN102008480A (en) | 2009-07-11 | 2010-07-08 | Irbesartan-containing composite preparation for treating hypertension |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910139980.2 | 2009-07-11 | ||
| CN200910139980 | 2009-07-11 | ||
| CN 201010230997 CN102008480A (en) | 2009-07-11 | 2010-07-08 | Irbesartan-containing composite preparation for treating hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102008480A true CN102008480A (en) | 2011-04-13 |
Family
ID=43838951
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010231025 Pending CN102008483A (en) | 2009-07-11 | 2010-07-08 | Candesartan-containing compound preparation for treating hypertension |
| CN 201010231105 Pending CN102008486A (en) | 2009-07-11 | 2010-07-08 | Compound preparation containing telmisartan for treating hypertension |
| CN 201010231028 Pending CN102008484A (en) | 2009-07-11 | 2010-07-08 | Olmesartan-containing compound preparation for treating hypertension |
| CN 201010231009 Pending CN102008482A (en) | 2009-07-11 | 2010-07-08 | Compound preparation containing valsartan for treating hypertension |
| CN 201010230997 Pending CN102008480A (en) | 2009-07-11 | 2010-07-08 | Irbesartan-containing composite preparation for treating hypertension |
| CN 201010231001 Pending CN102008481A (en) | 2009-07-11 | 2010-07-08 | Eprosartan-containing compound preparation for treating hypertension |
| CN 201010231095 Pending CN102008485A (en) | 2009-07-11 | 2010-07-08 | Losartan-containing compound preparation for treating hypertension |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010231025 Pending CN102008483A (en) | 2009-07-11 | 2010-07-08 | Candesartan-containing compound preparation for treating hypertension |
| CN 201010231105 Pending CN102008486A (en) | 2009-07-11 | 2010-07-08 | Compound preparation containing telmisartan for treating hypertension |
| CN 201010231028 Pending CN102008484A (en) | 2009-07-11 | 2010-07-08 | Olmesartan-containing compound preparation for treating hypertension |
| CN 201010231009 Pending CN102008482A (en) | 2009-07-11 | 2010-07-08 | Compound preparation containing valsartan for treating hypertension |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010231001 Pending CN102008481A (en) | 2009-07-11 | 2010-07-08 | Eprosartan-containing compound preparation for treating hypertension |
| CN 201010231095 Pending CN102008485A (en) | 2009-07-11 | 2010-07-08 | Losartan-containing compound preparation for treating hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (7) | CN102008483A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335177A (en) * | 2011-07-14 | 2012-02-01 | 海南锦瑞制药股份有限公司 | Brand-new oral solid pharmaceutical composition and preparation method thereof |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335178B (en) * | 2011-07-14 | 2012-12-26 | 海南锦瑞制药股份有限公司 | Oral solid pharmaceutical composition and preparation method thereof |
| CN102327272B (en) * | 2011-07-14 | 2013-08-14 | 海南锦瑞制药股份有限公司 | Oral solid pharmaceutical composition and preparation method thereof |
| CN102335176B (en) * | 2011-07-14 | 2013-06-05 | 海南锦瑞制药股份有限公司 | Brand-new oral solid medicinal composition and preparation method thereof |
| CN102342943B (en) * | 2011-07-14 | 2013-07-10 | 海南锦瑞制药股份有限公司 | Brand new oral solid medicinal composition and its preparation method |
| CN102342942B (en) * | 2011-07-14 | 2016-08-31 | 海南锦瑞制药有限公司 | A kind of New oral solid medicinal compositions and preparation method thereof |
| US10390016B2 (en) | 2011-11-04 | 2019-08-20 | Infobridge Pte. Ltd. | Apparatus of encoding an image |
| CN102512691A (en) * | 2012-01-10 | 2012-06-27 | 广州白云山天心制药股份有限公司 | Telmisartan composition and application thereof |
| CN102657657A (en) * | 2012-04-17 | 2012-09-12 | 北京哈三联科技股份有限公司 | Capsule containing valsartan, amlodipine and hydrochlorothiazide |
| CN103479643A (en) * | 2013-10-10 | 2014-01-01 | 沈阳药科大学 | Preparation method of compound preparation for treating high blood pressure |
| EP3219309A1 (en) * | 2016-03-17 | 2017-09-20 | K.H.S. Pharma Holding GmbH | Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension |
| CN106389431A (en) * | 2016-11-06 | 2017-02-15 | 成都先先先生物科技有限公司 | Compound pharmaceutical preparation for treating primary hypertension |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450211A (en) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | Composite antihypertensive preparation |
-
2010
- 2010-07-08 CN CN 201010231025 patent/CN102008483A/en active Pending
- 2010-07-08 CN CN 201010231105 patent/CN102008486A/en active Pending
- 2010-07-08 CN CN 201010231028 patent/CN102008484A/en active Pending
- 2010-07-08 CN CN 201010231009 patent/CN102008482A/en active Pending
- 2010-07-08 CN CN 201010230997 patent/CN102008480A/en active Pending
- 2010-07-08 CN CN 201010231001 patent/CN102008481A/en active Pending
- 2010-07-08 CN CN 201010231095 patent/CN102008485A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450211A (en) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | Composite antihypertensive preparation |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335177A (en) * | 2011-07-14 | 2012-02-01 | 海南锦瑞制药股份有限公司 | Brand-new oral solid pharmaceutical composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102008484A (en) | 2011-04-13 |
| CN102008483A (en) | 2011-04-13 |
| CN102008481A (en) | 2011-04-13 |
| CN102008485A (en) | 2011-04-13 |
| CN102008482A (en) | 2011-04-13 |
| CN102008486A (en) | 2011-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008480A (en) | Irbesartan-containing composite preparation for treating hypertension | |
| CN102008710B (en) | Lisinopril-containing compound preparation for treating hypertension | |
| TW200831078A (en) | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats | |
| CN101966189A (en) | Amlodipine and olmesartan-containing compound preparation for treating hypertension | |
| JP7050893B2 (en) | Angiotensin II receptor blocker for the prevention or treatment of systemic diseases in cats | |
| CN101966190A (en) | Amlodipine and eprosartan-containing compound preparation for treating hypertension | |
| EP2837380A1 (en) | Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof | |
| CN110325214A (en) | Low dose pharmaceutical combination for the prevention and treatment of neuronal damage | |
| Rajaram | Review of Captopril Drug Formulation, Mechanism of action, Dosage, Use and Adverse drug reactions | |
| CN101954082A (en) | Angiotensin-converting enzyme inhibitor-containing compound preparation for treating hypertension | |
| CN101590038B (en) | Oral sustained release hypotensive composition | |
| TW200920371A (en) | A combination treatment | |
| CN101125144A (en) | Compound medicine for treating diabetes | |
| CN101125143A (en) | Hypertension-treating compound medicine | |
| CN113616651B (en) | Compound antihypertensive pharmaceutical composition and application thereof | |
| CN101596203B (en) | Application of syringin in preparing drugs for treating cardiovascular and cerebrovascular diseases | |
| CN117243947A (en) | Application of daphnetin and combination containing daphnetin in preparation of diabetes complication medicaments | |
| CN107648225A (en) | A kind of antihypertensive Western medicine compound and preparation method thereof | |
| CN114617898A (en) | Compound preparation prepared from clindamycin and cimetidine and preparation method thereof | |
| US20220079920A1 (en) | Pharmaceutical composition containing amlodipine, chlorthalidone, and amiloride and application thereof | |
| CN102743361A (en) | Irbesartan hydrochlorothiazide capsule | |
| CN107814823A (en) | A kind of compound for treating diabetes and its application | |
| CN106361746A (en) | Compound medicine preparation capable of treating secondary hypertension | |
| KR20020021253A (en) | A cough inhibitory composition containing iron showing inhibitory effects on cough associated with angiotensin converting enzyme inhibitors | |
| CN105106962A (en) | Compound antihypertensive preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20110413 |